Committee on European Affairs and Oversight of the European Funds

ValueBlue Raises $11 Million to Fuel Agile Business Transformation Worldwide

Retrieved on: 
Tuesday, January 18, 2022
Octopus Group, APAC, European Commission Investment Plan for Europe, ABN AMRO, Union, Enterprise Architect (software), Enterprise, CEO, Digital, EA, A.S. Watson Group, Venture capital, Solution, Committee on European Affairs and Oversight of the European Funds, Health, CIOS, Industry, EFSI, Software as a service, Architecture, Wyndham Hotels & Resorts, Twitter, Microsoft, Coronavirus, Google, ABN, Financial services, Management, Cryptocurrency, Amazon, EMEA, Randstad, Deloitte

ValueBlue's collaborative EA platform provides unprecedented business insights that are crucial for planning and structuring as enterprises go digital.

Key Points: 
  • ValueBlue's collaborative EA platform provides unprecedented business insights that are crucial for planning and structuring as enterprises go digital.
  • ValueBlue has been addressing the growing need for agile business transformation since 2011 and the latest capital injection comes at a critical time.
  • ValueBlue is the leading company behind the Enterprise SaaS tool that helps CIOs and Enterprise Architects plan, collaborate, and manage business transformation.
  • The collaboration platform speeds up Agile Business Transformation for CIOs and Enterprise Architects across the globe.

BellaSeno Announces Publication of First-in-Human Data of its Lead Program Senella

Retrieved on: 
Tuesday, December 7, 2021
Environment, Risk, Company, Pectus excavatum, Queensland University of Technology, BMBF, CMO, Plastic surgery, BioCity Nottingham, University, Medtech, SAB, Patient, CEO, Committee on European Affairs and Oversight of the European Funds, Deformity, Princess Alexandra Hospital, Government, Education, Certification, Princess Alexandra Hospital, Brisbane, ISO, Senior lecturer, Polycaprolactone, Regional development, Doctor of Philosophy, European Journal, University of Queensland, Breast, PCL, Medical imaging

Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .

Key Points: 
  • Leipzig, Germany, December 07, 2021 BellaSeno GmbH , an ISO 13485-certified medtech company developing absorbable scaffolds using additive manufacturing technologies, today announced the publication of first-in-human data of its lead program Senella in the European Journal of Plastic Surgery .
  • The highly porous polycaprolactone implant was well tolerated by the patient and resulted in an excellent aesthetic outcome.
  • The case study describes the first-in-human trial of soft tissue engineering to camouflage a pectus excavatum defect not reconstructable by conventional techniques.
  • Senella therefore has the potential to alleviate the complications found in current breast reconstruction and augmentation approaches.

Median Technologies Announces New Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 With a Focus on Stage 1 Lung Cancer Characterization

Retrieved on: 
Tuesday, November 23, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NSCLC, Liver cancer, AI, International Association, Diagnosis, Prognosis, Lung cancer, LCS, EIB, Cade, CEO, RSNA, Cancer, Precision medicine, Liver disease, DS, National Lung Screening Trial, NLST, European Commission Investment Plan for Europe, Death, Research, HCC, BPI, Exhibition, Euronext Growth, Committee on European Affairs and Oversight of the European Funds, Solution, Survival, Radiology, Artificial intelligence, Literature, Ginkgo CADx, FDA, SME, Patient, Adoption, Biomarker, Technology, European Investment Bank, Non-small-cell lung carcinoma, Malignancy, Data science, NASH, AUC, Disease, Medical imaging

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces new outstanding performance of its lung cancer screening (LCS) CADx to characterize malignant vs. benign lung nodules.
  • New results specifically focus on the characterization of stage 1 lung cancer nodules, using Medians proprietary iBiopsy deep learning algorithm on low-dose chest computed tomography (LDCT).
  • Lung cancer is the number one cancer killer globally, causing an estimate of 1.8m deaths, accounting for 18% of all cancer deaths in 20202.
  • A noteworthy International Early Lung Cancer Action Program (I-ELCAP) cohort study of stage 1 cancer patients4 revealed an excellent 15-year LCS survival of 92% which again serves to show how critical early stage diagnosis via lung cancer screening remains.

Finnforel to Invest EUR 45 Million in New Production Facilities and Build First Selective Breeding Centre for Rainbow Trout in Finland

Retrieved on: 
Tuesday, November 9, 2021
Agriculture, Natural Resources, Environment, Food, Beverage, Consumer, Luxury, Other Consumer, Retail, Offshore aquaculture, Fish products, European Maritime Safety Agency, Genetics, Health, European Investment Bank, RAS, Egg, Technology, Investment, Recirculating aquaculture system, Multimedia, Research, Good, National Biodiesel Board, Board, EUR, Committee on European Affairs and Oversight of the European Funds, Farm, Lake, Finnish Institute for Health and Welfare, United Kingdom, Breeding, Aquaculture

Finnforel is further expanding the production capacity of its Varkaus plant from one million to three million kilos.

Key Points: 
  • Finnforel is further expanding the production capacity of its Varkaus plant from one million to three million kilos.
  • Since the early 1990s, Natural Resources Institute Finland has carried out pioneering research in rainbow trout genetics, breeding and animal health.
  • Finnforel is financing these investments totalling EUR 45 million through a EUR 34 million share issue, EUR 4.5 million from the European Maritime and Fisheries Fund (EMFF) and EUR 6 million in loans from banks.
  • The company's best-known brand is Saimaan Tuore, whose rainbow trout products are available in more than a thousand grocery stores throughout Finland.

Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers

Retrieved on: 
Friday, October 22, 2021
Biotechnology, Health, Other Health, Radiology, Pharmaceutical, Stem Cells, Oncology, Other Science, Research, Medical Devices, Infectious Diseases, Genetics, Science, Clinical Trials, Cloud, Curie Institute (Paris), Norwest Venture Partners, Ipsen, Organization, Partnership, SPAC, Boehringer Ingelheim, EFSI, Degenerative disease, European Commission Investment Plan for Europe, Therapy, Doctor of Philosophy, Takeda Pharmaceutical Company, Research, Quality of life, European Union, View, LP record, List of life sciences, INSERM, LSP, Lead, Education, Physician, Committee on European Affairs and Oversight of the European Funds, Industry, Investment, TVI, Immunity, CEO, Growth, Union, Gastroenterology, Institute, Cancer, Neurodegeneration, Patient, Neuroscience, Felice, BMS, Pharmaceutical industry, Vaccine, Financial services, Fine chemical, Egle Therapeutics, LSP, Bpifrance – InnoBio 2, Takeda Ventures Inc., Fund+, Bioqube Ventures, Institut Curie, EGLE THERAPEUTICS, LSP, BPIFRANCE – INNOBIO 2, TAKEDA VENTURES INC., FUND+, BIOQUBE VENTURES, INSTITUT CURIE

The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund.

Key Points: 
  • The Series A was co-led by LSP and Bpifrance through their InnoBio 2 fund.
  • The new capital will be used primarily to advance 2 leads assets into the clinic and further strengthen its internal drug pipeline.
  • The investor syndicate will join the Egle Therapeutics Board which will consist of Felice Verduyn-van Weegen (LSP), Vincent Brichard (LSP), Jean-Francois Morin (Bpifrance InnoBio 2) and Sacha Mann (Takeda Ventures).
  • Philippe Monteyne (Fund+), Jacques Mizrahi (Bioqube Ventures) and Elisa El Nouchi (Bpifrance InnoBio 2) will join as observers.

EU Malaria Fund Enters Post-investment Period

Retrieved on: 
Thursday, October 7, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Infection, Vaccine, Small Business Innovation Research, Commissioner, European Investment Bank, Berlin, EIB, European, BioNTech, Bill, Royal commission, Education, Novartis, Program, Culture, Committee on European Affairs and Oversight of the European Funds, Disease, World, COVID-19, Technology, EU, European Commission, Innovation, Investment, SE, Bill & Melinda Gates Foundation, HIV, EMA, Tuberculosis, Poverty, Pharmaceutical industry

On 30 September, the EU Malaria Fund (EUMF) concluded its investment activities at a high-level online event by finalizing its investments into four innovative companies active in malaria R&D.

Key Points: 
  • On 30 September, the EU Malaria Fund (EUMF) concluded its investment activities at a high-level online event by finalizing its investments into four innovative companies active in malaria R&D.
  • The EUMF is grateful to the European Commission and the European Investment Bank (EIB), the major contributors to the Fund through the InnovFin EU programme funded by EU Horizon 2020 and the European Fund of Strategic Investments.
  • Pedro Alonso, Director of the World Health Organizations Global Malaria Programme, states: The EU Malaria Fund is a great example how innovative new instruments can ultimately lead to impact.
  • I would like to thank everyone involved in the EU Malaria Fund project for their contribution to fighting malaria.

DGAP-News: Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)

Retrieved on: 
Monday, September 6, 2021
European Union, Sodium channel blockers, Drugs, Multilateral development banks, Financial services, Calcium channel blockers, Monoamine oxidase inhibitors, Economy of the European Union, InvestEU, Zambon, Safinamide, European Investment Bank

The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.

Key Points: 
  • The EIB loan is backed by the European Fund for Strategic Investments (EFSI), the central pillar of the Investment Plan for Europe.
  • Tranche 4 consists of EUR 7.5 million and will primarily be used to support the Company's development programs in diseases of the central nervous system.
  • The first three tranches of the loan totaling EUR 25 million were received by Newron in 2019 and 2020.
  • Newron is developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Median Technologies Announces Outstanding Performance for its iBiopsy® Lung Cancer Screening CADx1 to Accurately Characterize Malignant vs Benign Lung Nodules Based on a Large-scale Patient Cohort

Retrieved on: 
Monday, September 6, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Medicine, Lung cancer, Medical tests, Clinical medicine, Health, Radiology, Lung nodule, Screening, Cancer screening, Cancer, CT scan, Oncology

Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.

Key Points: 
  • Median Technologies (Paris:ALMDT) (ALMDT:PA) announces outstanding performance based on a large-scale lung cancer screening (LCS) patient cohort to characterize malignant vs benign lung nodules based on a deep learning algorithm on low-dose chest computed tomography.
  • The Median Technologies iBiopsy Lung Cancer Development Plan was launched in February 2021 , as part of the Companys strategic positioning in early-stage disease diagnosis.
  • Major international studies have shown that LDCT lung cancer screening can reduce mortality by 44% (NELSON Trial, 2018).
  • The study was based on a cohort of 1,696 patients from the National Lung Screening Trial cases (NLST) consisting of a total of 15,608 lung nodules.